MRD as assessed in the BM. (A) NPM1 MRD measured by quantitative reverse transcription PCR after each treatment cycle. Patients with NPM1 and FLT3 mutations treated with DAGO (n = 55) without midostaurin in AML19v1 are shown for comparison. (B) NPM1 MRD by GO dose for patients in the Midotarg substudy. (C) FLT3-ITD next-generation sequencing (NGS) MRD after treatment cycles 1 and 2. Patients with FLT3-ITD mutations treated with DAGO without midostaurin in AML19v1 are shown for comparison. (D) FLT3-ITD NGS MRD by GO dose for patients in Midotarg substudy. CN, copy number; Mido, midostaurin; VAF, variant allele frequency.